Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

BackgroundThe phase 3 clinical trial KEYNOTE-426 suggested a higher efficacy regarding overall survival (OS) and progression-free survival (PFS) of pembrolizumab+axitinib compared to sunitinib as a first-line treatment for patients with advanced renal cell carcinoma. In this analysis, the potential...

Full description

Bibliographic Details
Main Authors: Nicolas S. H. Xander, W. Edward Fiets, Carin A. Uyl-de Groot
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness
budget impact
pembrolizumab
axitinib
sunitinib
renal cell carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1205700/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1205700/full

Similar Items